LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. - Wikidata - wikimedia - TriplyDB

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

http://www.wikidata.org/entity/Q33740256

about

A systematic screen for micro-RNAs regulating the canonical Wnt pathway Mammary Development and Breast Cancer: A Wnt Perspective Frizzled7: A Promising Achilles' Heel for Targeting the Wnt Receptor Complex to Treat Cancer Development of anticancer agents targeting the Wnt/β-catenin signaling Targeting the Wnt pathways for therapies Frizzled homolog proteins, microRNAs and Wnt signaling in cancer Ductal barriers in mammary epithelium Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.The LRP6 rs2302685 polymorphism is associated with increased risk of myocardial infarction.Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept.Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6 Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers Repression of Wnt signaling by a Fer-type nonreceptor tyrosine kinase.Prescriptions of traditional Chinese medicine are specific to cancer types and adjustable to temperature changes.Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion Tyrosine-based signal mediates LRP6 receptor endocytosis and desensitization of Wnt/β-catenin pathway signaling.MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2.Wnt and mammary stem cells: hormones cannot fly wingless.Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease.FH535 inhibited migration and growth of breast cancer cells.Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.Key signaling nodes in mammary gland development and cancer: β-catenin.Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/β-catenin signaling in human hepatocellular carcinoma.DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression Mammary cells with active Wnt signaling resist ErbB2-induced tumorigenesis Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling.Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells.Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target.Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells.Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3 Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.

P2860

Q21134995-DE19E424-AC75-4B88-A349-917724540DF4 Q26740086-A0178723-EC9B-4D6B-B4A1-D283A66BA096 Q26747651-8647E181-761D-49F1-B64F-EA78CCD453F9 Q26781898-0F741326-DB40-4C91-A042-398B6E7CBD11 Q26821978-F206D4DD-9906-49C2-BA0D-A3C3C97F9937 Q27010132-DF7CC798-45B6-4FE7-A565-20DC6A0947B8 Q27023960-79E37634-EB02-4DC8-A930-1E87A41020F9 Q28478466-A26B1FDD-8D70-4D25-8CEA-2BAFEFE6282E Q28535721-75431D1C-47BF-4F41-9BE7-A4B8690DBAF1 Q33685717-6D18F3A2-C539-4492-8D63-5D74BBE18480 Q33761093-008882AE-A3D6-441A-8498-8557BB18BE30 Q33889275-8A7C7150-85C9-46E3-B513-1ECCE2648D04 Q33939375-C6E86D7E-3100-4154-B692-C45539329832 Q34052780-D9FA3338-7B8C-478B-B239-4DEF508C8019 Q34119756-8054CEC0-209D-4444-8BF7-079416A0BA66 Q34136391-F0B81E61-FA9E-403F-B66C-7E60F1EC0509 Q34168327-F937B0E5-0AD9-4371-AF5D-AD46F3B35F95 Q34263359-1A5F1FC9-1837-4272-A25A-CF0086016F77 Q34283427-C6FE4EBD-D9E2-4284-8157-382E98495473 Q34306118-9DB23990-F56F-4EF4-9323-9ED7BF437CE7 Q34311270-03884F67-0CEE-4047-9E7B-65B7C34DDEDF Q34350189-ED728F70-6861-4350-A090-50B7AC3E7502 Q34415881-46D73926-A366-4654-92AE-D0FF8B4935F6 Q34443640-74526B32-84BC-430F-A461-5FC7D8798F0C Q34612838-7BA67B27-7807-4268-8D29-20C1F9A0A878 Q34613461-F2B8A764-F97A-4DEC-AE40-04D73E2EB825 Q34967879-3A668962-15C9-4050-97FF-CE768A90C3D2 Q35021360-5B40A44E-2EB1-499B-AA0A-E3BBE68874CF Q35050344-29D76C96-A603-4A34-B668-A010C90E2649 Q35083176-5C06071D-105C-4592-952B-F981E5A13D4E Q35164584-4315BECF-A043-4601-B808-858CB642AAEB Q35179258-0A1CD425-86E5-46F4-B8F2-BEDE62475AAF Q35243349-2E18F501-CFB6-41BB-A669-F4445DE73BD7 Q35300556-AD207224-6D01-4E4C-B3E6-B25444C6FE22 Q35542572-F069D8BD-D022-414C-A75E-22CF31FC71EE Q35558027-F3D91338-1FAE-4316-9841-17162E144D0B Q35956457-18D7A405-7EC6-4EEC-BA91-08C0F5E61720 Q36303639-0831D2E1-9896-48DA-9361-A27A3CF49CBE Q36329477-F8CD3534-3428-49A8-B5BF-9DBB3AC8DA8D Q36647355-2AC9138C-A599-4F0A-9D51-773A1CEE7AAA

P2860

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

http://www.wikidata.org/entity/Q33740256

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@ast

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@en

type

label

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@ast

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@en

prefLabel

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@ast

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@en

P1433

Q33740256-AB90EE68-4FEC-4B87-8E4D-876466FF7609

P1476

Q33740256-DD317621-8E83-4426-959E-7348060286F1

P2093

Q33740256-057ED556-70BF-4110-B292-D2EE4C924A6A

Q33740256-34FD7448-34D7-48A6-9962-3B984A27AB8A

Q33740256-44EF17F0-FF87-45BA-8A48-1DD47AB4D118

Q33740256-B9FE6B0D-5B41-4A0D-B814-E5021A9898E1

P2860

Q33740256-09CB95D8-3361-42F8-9D8E-2D8A62BA049D

Q33740256-0B736BC9-6BA9-4A8B-A950-23A86B99D805

Q33740256-26686D3A-9F70-4F39-BA1E-9C5C8E26DEDA

Q33740256-33239DC2-1ADE-4F0A-B748-C3B79BDB1F84

Q33740256-36CAFB0F-C833-4A8E-9C38-AA0B734BD032

Q33740256-37ECCB27-DDB8-44D5-81C7-C2FB15C2F948

Q33740256-41FFB454-3A51-4608-9317-DE2A444E0750

Q33740256-4A225876-907D-4B3E-B12D-68039C406530

Q33740256-51BA81F1-CFC1-4013-BEB3-BA438F009296

Q33740256-54246AAF-FC8D-4C67-A04C-B0C01581D8BB

P304

Q33740256-4DCB0E75-56EA-4161-A0B1-7C404813DDEB

P31

Q33740256-4E3DB585-1F11-4E32-9715-1C488D037E6C

P356

Q33740256-0D4678BE-C204-4586-997C-F35D5D17125B

P407

Q33740256-8F552609-F201-44B8-B0F5-29DC4F8173D6

P433

Q33740256-1ECE9097-4907-46F7-B2E0-B611A7B92F71

P478

Q33740256-4B34E9EF-7CFD-45C1-83AE-D282FFEF1A3F

P577

Q33740256-344F558D-5589-4892-8AF1-4EB582AD267E

P5875

Q33740256-1C6D46DD-3AB9-461C-92D1-D16BA7B8A2DF

P698

Q33740256-21E14D72-D35A-4140-8710-03BF21BACD8C

P921

Q33740256-45E3606A-C405-4148-B313-D1799CE35B59

P932

Q33740256-C75A5775-C754-4136-915C-255B7B856DAF

P356

PNAS.0911220107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

@en

P2093

Chia-Chen Liu

http://www.w3.org/2001/XMLSchema#string

David Piwnica-Worms

http://www.w3.org/2001/XMLSchema#string

Guojun Bu

http://www.w3.org/2001/XMLSchema#string

Julie Prior

http://www.w3.org/2001/XMLSchema#string

P2860

LDL-receptor-related proteins in Wnt signal transduction

Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding

Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism

The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway

Humanization of an anti-p185HER2 antibody for human cancer therapy

Wnt signaling, lgr5, and stem cells in the intestine and skin

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Wnt signaling in breast cancer: have we come full circle?

Wnt/beta-catenin signaling in development and disease

beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin

P304

5136-5141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0911220107

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41656823

http://www.w3.org/2001/XMLSchema#string

P698

20194742

http://www.w3.org/2001/XMLSchema#string

P921

P932

2841938

http://www.w3.org/2001/XMLSchema#string